Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Meet us at #Tandem24
Meet our medical team to find out more about our clinical program and CAR-T therapies on February 21-25 in San Antonio, Texas.
Meet us at #Tandem24
Meet our medical team to find out more about our clinical program and CAR-T therapies on February 21-25 in San Antonio, Texas.
We are looking forward to your visit during #Tandem24
We are excited to be present at the 2024 Tandem Meetings of ASTCT™ and CIBMTR®, February 21-25 in San Antonio, Texas. We look forward to welcoming you to our booth where you will be able to speak to our medical team about our clinical program and open trials.
#Tandem24 will take place at the Henry B. González Convention Center, 900 E Market St, San Antonio, TX 78205. You will find us at the Miltenyi Biomedicine booth 620.
Exhibition opening hours:
Wednesday, February 21 – Saturday, February 24, 2023 (9:00 AM – 3:00 PM ET)
Latest resources and news about Miltenyi Biomedicine presented at #Tandem24
DALY 2-EU trial –
now recruiting
Visit official trial page
Downloads and preview links
Take a view at our recent posters and presentations
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
